Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIPER Chemotherapy in Relapsed and Refractory Diffuse Large B-cell Lymphoma
NCT00504751Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- May 2007
- Primary completion
- Dec 2010
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in diffuse large B-cell lymphoma (DLBCL), sponsored by Weill Cornell Medicine. Primary endpoint: Complete Response at 26 months. Started May 2007; status: completed.
02
Drugs
bortezomib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00504751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00504751.